Top Markets
#1 Black Phoenix Black Phoenix +195.60%
#2 Islamic Coin Islamic Coin +158.06%
#3 Glidr Glidr +84.34%
#4 Gold Park Gold Park +34.69%
#5 Acurast Acurast +29.19%
#6 Cryptopia Cryptopia +21.79%
#7 Quantum Resistant Ledger Quantum Resistant Ledger +17.72%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +16.57%
#9 Playnance Playnance +13.33%
#10 wojak wojak +12.65%
Coin of the day
Black Phoenix Black Phoenix
Настройки
Язык
Pусский
Валюта
USD
Тема
VIA Pharmaceuticals, Inc. VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc.

VIAP
Ранг среди акций #41780
VIA Pharmaceuticals, Inc. is an emerging biotechnology company primarily... VIA Pharmaceuticals, Inc. is an emerging biotechnology company primarily focused on discovering and advancing therapeutic compounds for cardiovascular and metabolic disorders. The firm is building a portfolio of small-molecule drug candidates designed to tackle the root causes of these health issues, such as vascular inflammation, elevated cholesterol and triglyceride levels, and insulin resistance or diabetes. Notable candidates in their development pipeline include: VIA-3196: A liver-specific thyroid hormone receptor (THR) beta agonist, poised for Phase 1 clinical studies. This drug aims to mitigate dyslipidemia, addressing high LDL cholesterol, elevated triglycerides, and Lp(a) levels. A Diacylglycerol Acyl Transferase 1 (DGAT1) inhibitor: Currently in preclinical development for treating type 2 diabetes, with promising potential for weight management and other lipid disorders. VIA-2291: A 5-Lipoxygenase inhibitor that has successfully completed its third Phase 2 clinical trial. Its purpose is to target atherosclerotic plaque, a significant contributor to heart attacks, strokes, and various other vascular diseases. VIA Pharmaceuticals has also forged two research, development, and commercialization agreements with Hoffman-LaRoche Inc. and Hoffman-LaRoche Ltd. These collaborations pertain to their THR beta agonist program and several compounds from their preclinical DGAT1 metabolic disorders initiative. Established in 2004, the company's headquarters are located in San Francisco, California.
Цена акции
$0.0005
Последняя синхронизация: 2026-08-11
Рыночная капитализация
$10.28K
Изменение (1 день)
0.00%
Изменение (1 год)
0.00%
Страна
US
Торговля VIA Pharmaceuticals, Inc. (VIAP)

Категория

Healthcare
История дроблений акций VIA Pharmaceuticals, Inc. (VIAP)
Акции VIA Pharmaceuticals, Inc. (символ: VIAP) прошли через 0 дроблений.
Последнее дробление произошло Aug 13, 2026.
Одна акция VIAP, купленная до Aug 13, 2026, сейчас соответствует 0 акциям VIAP.
Список дроблений акций
Год Дробление Коэффициент Суммарный коэффициент
Недостаточно данных для указанных дат.
Дробления акций аналогичных компаний или конкурентов
Компания Количество дроблений акций Суммарный коэффициент Страна
Royalty Pharma plc Royalty Pharma plc
Royalty Pharma plc
RPRX.US
 0 -
US
Swedish Orphan Biovitrum AB Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB
SOBI.ST
 0 -
SE
Ipsen S.A. Ipsen S.A.
Ipsen S.A.
IPN.PA
 0 -
FR
Recordati Industria Chimica e Farmaceutica S.p.A. Recordati Industria Chimica e Farmaceutica S.p.A.
Recordati Industria Chimica e Farmaceutica S.p.A.
REC.MI
 0 -
IT
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated
CORT.US
 0 -
US